Helou

Despite recent advances in understanding pulmonary fibrosis, therapeutic options remain limited and often ineffective. Inflammation plays a key role in this disease, but many of the immune mechanisms that regulate it remain poorly understood. The MIFIP junior research group is dedicated to studying the immunomodulatory mechanisms involved in pulmonary fibrosis. In particular, we are interested in the role of immune checkpoints in this context. These receptors, which have revolutionized cancer therapies, could also represent a promising avenue for modulating the immune response in pulmonary fibrosis and paving the way for new therapeutic strategies. Our group is supported by two ANR grants (CPJ and JCJC), an Inserm Proof of Concept grant, as well as funding from the Fondation du Souffle and Sanofi. We also collaborate with several industrial partners, notably genOway, which allows us to evaluate immunomodulatory treatments in humanized mouse models.